Jubilant Therapeutics Inc, a US-based clinical-stage biopharmaceutical company advancing precision therapies for hematological malignancies, announced on Tuesday the presentation of the first clinical data from its ongoing Phase 1/2 study of JBI-802, the company's first-in-class oral dual LSD1/HDAC6 inhibitor, at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting in Houston, Texas.

The data demonstrated the first clinical evidence supporting dual inhibition of LSD1 and HDAC6 as a differentiated therapeutic approach for patients with myeloproliferative neoplasms (MPNs), a group of blood cancers, including essential thrombocythemia (ET) and polycythemia vera (PV).

The presentation reported clinical activity across patients (n = 12) with ET, PV, myelofibrosis (MF) and myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN), with rapid, sustained and durable, dose-dependent reductions in platelet counts with a manageable safety profile.

According to Jubilant, JBI-802 is the only oral dual LSD1/HDAC6 inhibitor currently in clinical development. Administered once daily, JBI-802 is designed to simultaneously inhibit LSD1 and HDAC6, two complementary epigenetic regulators involved in the abnormal blood cell proliferation and production characteristic of MPNs. Preclinical studies have suggested that dual inhibition may provide broader biological activity than selective inhibition of either pathway alone.

The ongoing Phase 1/2 study is evaluating JBI-802 in patients with relapsed, refractory, or treatment-intolerant MPNs. Study objectives include evaluation of safety and tolerability, identification of the recommended Phase 2 dose, and assessment of preliminary efficacy through platelet reduction, durability of hematologic response, and molecular outcomes.

Enrolment is ongoing and Jubilant Therapeutics expects to present additional efficacy, safety, and molecular response data as the program advances.